Pfizer Inc. (NYSE:PFE) Shares Bought by Ossiam

Ossiam increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 44.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 265,695 shares of the biopharmaceutical company's stock after purchasing an additional 81,496 shares during the period. Ossiam's holdings in Pfizer were worth $7,049,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. PSI Advisors LLC lifted its stake in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after buying an additional 391 shares during the period. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares during the period. Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC grew its holdings in Pfizer by 2.2% during the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.3 %

Shares of NYSE:PFE traded down $0.07 during trading on Monday, reaching $22.07. The stock had a trading volume of 31,814,050 shares, compared to its average volume of 40,452,372. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $125.17 billion, a P/E ratio of 15.65, a PEG ratio of 0.64 and a beta of 0.67. The firm's 50-day simple moving average is $24.81 and its 200 day simple moving average is $26.11. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The business's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PFE shares. UBS Group cut their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.